Enzo Biochem (ENZ) Stock Price
Enzo Biochem Price
Over the last 19 years Enzo Biochem grew revenue by 18.4% annually, reaching 992.90 M USD. Earnings per share have declined at 30.0% per year over the last 5 years. For Enzo Biochem, the net margin of -0.8% is down versus 6.7% a few years ago. At today's price the dividend yield works out to roughly 31.87%.
Enzo Biochem stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Enzo Biochem over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Enzo Biochem stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Enzo Biochem's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Enzo Biochem Price |
|---|
Enzo Biochem Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Enzo Biochem Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97.00 | 102.00 | 103.00 | 93.00 | 95.00 | 97.00 | 102.00 | 105.00 | 101.00 | 81.00 | 76.00 | 117.00 | 32.00 | 871.00 | 31.00 | 992.00 |
| 8.99 | 5.15 | 0.98 | -9.71 | 2.15 | 2.11 | 5.15 | 2.94 | -3.81 | -19.80 | -6.17 | 53.95 | -72.65 | 2,621.88 | -96.44 | 3,100.00 |
| 46.39 | 47.06 | 45.63 | 40.86 | 43.16 | 43.30 | 44.12 | 42.86 | 39.60 | 28.40 | 30.26 | 45.30 | 40.63 | 7.35 | 45.16 | 7.06 |
| 45.00 | 48.00 | 47.00 | 38.00 | 41.00 | 42.00 | 45.00 | 45.00 | 40.00 | 23.00 | 23.00 | 53.00 | 13.00 | 64.00 | 14.00 | 70.00 |
| -22.00 | -13.00 | -39.00 | -18.00 | -10.00 | -2.00 | 45.00 | -2.00 | -10.00 | 2.00 | -28.00 | 7.00 | -18.00 | -11.00 | -26.00 | -8.00 |
| -4.35 | -40.91 | 200.00 | -53.85 | -44.44 | -80.00 | -2,350.00 | -104.44 | 400.00 | -120.00 | -1,500.00 | -125.00 | -357.14 | -38.89 | 136.36 | -69.23 |
| 38.00 | 38.40 | 38.80 | 39.60 | 42.60 | 45.40 | 46.60 | 46.40 | 47.00 | 47.50 | 47.70 | 48.33 | 48.59 | 157.25 | 50.90 | 138.87 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Enzo Biochem generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Enzo Biochem retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Enzo Biochem's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Enzo Biochem has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Enzo Biochem's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Enzo Biochem stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Enzo Biochem Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Enzo Biochem business model & stock analysis
Enzo Biochem SWOT Analysis
Strengths
Enzo Biochem Inc. possesses several strengths that contribute to its competitive advantage:
- Strong patent portfolio: Enzo Biochem holds a significant number of patents for its innovative technologies and products, providing a solid foundation for future growth.
- Diverse product portfolio: The company offers a wide range of products and services, including molecular biology reagents, diagnostic kits, and clinical laboratory services, which helps to diversify its revenue streams and mitigate risk.
- Strategic partnerships: Enzo Biochem has established strategic collaborations with leading research institutions and healthcare organizations, facilitating access to new markets, expertise, and resources.
- Experienced management team: The company is led by a highly skilled and knowledgeable management team with extensive industry experience, ensuring effective decision-making and execution of growth strategies.
Weaknesses
Despite its strengths, Enzo Biochem Inc. faces certain weaknesses that could hinder its performance:
- High research and development costs: Developing cutting-edge products and technologies requires substantial investment in research and development, potentially straining the company's financial resources.
- Reliance on key customers: Enzo Biochem heavily depends on a few key customers for a significant portion of its revenue, making it vulnerable to potential changes in demand or loss of business from these customers.
- Limited global presence: The company's operations are primarily concentrated in certain regions, limiting its exposure to international markets and potential growth opportunities.
Opportunities
Enzo Biochem Inc. can capitalize on various opportunities to enhance its market position and profitability:
- Expanding product offerings: The company can further diversify its product portfolio by investing in new research and development initiatives, potentially addressing unmet needs in the healthcare and life sciences sectors.
- Growing demand for personalized medicine: The increasing focus on personalized medicine presents an opportunity for Enzo Biochem to develop and commercialize advanced diagnostic tools and therapies tailored to individual patients.
- Emerging markets: Penetrating emerging markets, such as Asia and Latin America, can provide Enzo Biochem with new avenues for revenue growth, given the rising healthcare expenditure and increasing awareness about advanced healthcare technologies.
Threats
Enzo Biochem Inc. faces several threats that could impact its business and market position:
- Intense competition: The life sciences and molecular diagnostics industry is highly competitive, with numerous established players and new entrants constantly vying for market share. This could put pressure on Enzo Biochem's pricing and profitability.
- Regulatory challenges: Compliance with evolving regulations, such as those related to clinical laboratory operations and the approval process for new products, can pose challenges and lead to delays in commercialization.
- Economic uncertainties: Fluctuations in the global economy, such as recessions or economic downturns, can impact healthcare spending and investment in research and development, influencing Enzo Biochem's revenue growth and profitability.
Enzo Biochem Segments
Enzo Biochem Revenue by Segment (1/9)
3 Years
5 Years
10 Years
25 Years
Max
Details
Enzo Biochem Revenue by Segment (2/9)
3 Years
5 Years
Max
Details
Enzo Biochem Revenue by Segment (3/9)
3 Years
5 Years
Max
Details
Enzo Biochem Revenue by Segment (4/9)
3 Years
5 Years
Max
Details
Enzo Biochem Revenue by Segment (5/9)
3 Years
5 Years
Max
Details
Enzo Biochem Revenue by Segment (6/9)
3 Years
5 Years
Max
Details
Enzo Biochem Revenue by Segment (7/9)
3 Years
5 Years
Max
Details
Enzo Biochem Revenue by Segment (8/9)
3 Years
5 Years
Max
Details
Enzo Biochem Revenue by Segment (9/9)
3 Years
5 Years
Max
Details
Enzo Biochem Revenue by Region
3 Years
5 Years
Max
Details
Enzo Biochem Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Enzo Biochem historical P/E ratio, EBIT multiple, and P/S ratio
Enzo Biochem annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Enzo Biochem shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Enzo Biochem stock splits
Enzo Biochem Dividend History
1 years of dividend payments
Enzo Biochem dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Enzo Biochem Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 6/10/2019 | -0.15USD | 19.60 MUSD | 2019 Q3 |
| 3/11/2019 | -0.13USD | 21.32 MUSD | 2019 Q2 |
| 12/10/2018 | -0.11USD | 21.44 MUSD | 2019 Q1 |
| 10/15/2018 | -0.06USD | 25.64 MUSD | 2018 Q4 |
| 6/11/2018 | -0.02USD | 28.34 MUSD | 2018 Q3 |
| 3/12/2018 | -0.01USD | 27.76 MUSD | 2018 Q2 |
| 12/7/2017 | -0.01USD | 27.89 MUSD | 2018 Q1 |
| 9/27/2017 | -0.02USD | 27.81 MUSD | 2017 Q4 |
| 6/8/2017 | -0.03USD | 27.91 MUSD | 2017 Q3 |
| 3/13/2017 | -0.04USD | 26.49 MUSD | 2017 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Enzo Biochem stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Enzo Biochem shareholder structure
| % | Name |
|---|---|
7.80541% | |
3.65078% | |
3.55905% | |
0.33286% | |
0.08857% | |
0.03242% |
Enzo Biochem Executives and Management Board
Ms. Kara Cannon
(56)Chief Executive Officer, Chief Operating Officer · since 2011
Patricia Eckert
(65)Chief Financial Officer
Mr. Brian Fisher
(54)General Counsel, Secretary
Enzo Biochem Supply Chain
Enzo Biochem Supply Chain
Correlation: how closely stock prices move together
| # | Name | 1M | 3M | 6M | 1Y | 2Y | Trend |
|---|---|---|---|---|---|---|---|
| 1 | 0.81 | 0.79 | 0.40 | 0.51 | 0.76 | ||
| 2 | -0.34 | 0.27 | 0.48 | 0.52 | 0.71 | ||
| 3 | 0.57 | 0.22 | -0.43 | -0.51 | 0.47 |
Frequently asked questions about Enzo Biochem
Enzo Biochem Inc is a life sciences and biotechnology company. Its business model encompasses the development, manufacturing, and commercialization of innovative diagnostic and research products. The company offers a diverse range of products and services catering to the life sciences industry. These include molecular diagnostics, immunohistochemistry, flow cytometry, and drug discovery research tools. Enzo Biochem Inc also operates clinical reference laboratories that provide a wide array of testing services. By leveraging its proprietary technology platforms, the company aims to facilitate advancements in personalized medicine and scientific research. Through collaborations and strategic partnerships, Enzo Biochem Inc strives to contribute to advancements in healthcare and improve patient outcomes.
Enzo Biochem stock
Enzo Biochem Peer Group
Enzo Biochem Ticker
Enzo Biochem FIGI
All fundamentals and in-depth analysis of Enzo Biochem
Our stock analysis for Enzo Biochem stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Enzo Biochem. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.